Couñago Felipe, de la Pinta Carolina, Gonzalo Susana, Fernández Castalia, Almendros Piedad, Calvo Patricia, Taboada Begoña, Gómez-Caamaño Antonio, Guerra José Luis López, Chust Marisa, González Ferreira José Antonio, Álvarez González Ana, Casas Francesc
Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Hospital La Luz, Universidad Europea de Madrid, Madrid 28223, Madrid, Spain.
Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid 28034, Spain.
World J Clin Oncol. 2021 Mar 24;12(3):115-143. doi: 10.5306/wjco.v12.i3.115.
Small cell lung cancer (SCLC) accounts for approximately 20% of all lung cancers. The main treatment is chemotherapy (Ch). However, the addition of radiotherapy significantly improves overall survival (OS) in patients with non-metastatic SCLC and in those with metastatic SCLC who respond to Ch. Prophylactic cranial irradiation reduces the risk of brain metastases and improves OS in both metastatic and non-metastatic patients. The 5-year OS rate in patients with limited-stage disease (non-metastatic) is slightly higher than 30%, but less than 5% in patients with extensive-stage disease (metastatic). The present clinical guidelines were developed by Spanish radiation oncologists on behalf of the Oncologic Group for the Study of Lung Cancer/Spanish Society of Radiation Oncology to provide a current review of the diagnosis, planning, and treatment of SCLC. These guidelines emphasise treatment fields, radiation techniques, fractionation, concomitant treatment, and the optimal timing of Ch and radiotherapy. Finally, we discuss the main indications for reirradiation in local recurrence.
小细胞肺癌(SCLC)约占所有肺癌的20%。主要治疗方法是化疗(Ch)。然而,对于非转移性SCLC患者以及对Ch有反应的转移性SCLC患者,加用放射治疗可显著提高总生存期(OS)。预防性颅脑照射可降低脑转移风险,并改善转移性和非转移性患者的OS。局限期(非转移性)患者的5年OS率略高于30%,但广泛期(转移性)患者的5年OS率低于5%。本临床指南由西班牙放射肿瘤学家代表肺癌研究肿瘤学组/西班牙放射肿瘤学会制定,旨在对SCLC的诊断、计划和治疗进行当前综述。这些指南强调了治疗野、放射技术、分割方式(分次放疗)、同步治疗以及化疗和放疗的最佳时机。最后,我们讨论了局部复发时再次放疗的主要适应证。